THE INVESTOR

메뉴열기
October 24, 2019

Medytox invests in US startup LifeSprout

PUBLISHED : September 16, 2019 - 15:25

UPDATED : September 16, 2019 - 15:25

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

Medytox has participated in the seed-funding round of US startup LifeSprout, according to industry sources on Sept. 16.

Although the Korean company declined to confirm the specific amount that it has funded, a local news outlet reported that it invested around $1.5 million in this round.




The US company secured $6.5 million in total from investors, including Kairos Venture Partners, Triskelion Investments, Maryland Technology Development Corporation, Ginkgo Gofar, and AngelMD also join LifeSprout’s seed-funding round as a strategic investor.

“We saw potential in this startup and decided to take part in this round and invest. This is also a part of our goal to expand our presence in the global market,” a Medytox spokesperson told The Investor. The company added that it plans to make additional investments in global startups.

In 2015, LifeSprout was founded out of Johns Hopkins University. Currently, it mainly develops products for aesthetic and regenerative medicine. The company has Regenerative Matrix platform, which can support products that look and feel like the body’s tissues.

The seed funding money is expected to be used for further developing next-generation aesthetic filler Lumina, which is the company’s first product from the regenerative matrix platform.

By Song Seung-hyun (ssh@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.